Tacrolimus Concentration/Dose Ratio is Associated with Renal Function After Liver Transplantation

Ann Transplant. 2016 Mar 22:21:167-79. doi: 10.12659/aot.895898.

Abstract

Background: The calcineurin inhibitor (CNI) tacrolimus (Tac) is an effective immunosuppressant used after liver transplantation (LTx), but is often associated with CNI nephrotoxicity. Currently, there is no simple clinical predictor for CNI nephrotoxicity after LTx. We hypothesized that the Tac metabolism rate - defined as the blood concentration normalized by its daily dose (the C/D ratio) - is associated with post-LTx renal impairment.

Material and methods: We analyzed the relationship between the C/D ratio and post-transplant renal function in 179 patients who underwent LTx between 2000 and 2012 and were initially immunosuppressed with Tac, mycophenolate mofetil, and prednisolone. Six months after LTx, 115 patients were categorized into 1 of 2 groups based on their Tac C/D ratio (<1.09 or ≥1.09): fast (n=58) or slow (n=57) metabolizers. The renal function was determined 36 months after LTx using the estimated glomerular filtration rate (eGFR) as described by Cockcroft and Gault.

Results: At the time of LTx there was no statistically significant difference between the eGFR of fast and slow metabolizers. Six months (P=0.016), 12 months (P=0.001), and 36 months (P=0.018) after LTx, fast Tac metabolizers had significantly more impaired renal function than slow metabolizers. Because of a presumption of CNI nephrotoxicity, 32.8% of fast metabolizers and 14.0% of slow metabolizers were switched from Tac to other immunosuppressants (P=0.027).

Conclusions: In this study, the Tac metabolism rate appears to influence renal function after LTx, suggesting that a C/D ratio of <1.09 is associated with increased CNI nephrotoxicity in LTx recipients.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Graft Rejection / prevention & control
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / blood
  • Immunosuppressive Agents / therapeutic use
  • Inactivation, Metabolic
  • Liver Transplantation*
  • Male
  • Middle Aged
  • Outcome Assessment, Health Care
  • Postoperative Complications / blood
  • Postoperative Complications / chemically induced*
  • Postoperative Complications / diagnosis
  • Renal Insufficiency / blood
  • Renal Insufficiency / chemically induced*
  • Renal Insufficiency / diagnosis
  • Retrospective Studies
  • Tacrolimus / adverse effects*
  • Tacrolimus / blood
  • Tacrolimus / therapeutic use
  • Young Adult

Substances

  • Immunosuppressive Agents
  • Tacrolimus